Kalra Sanjay, Latif Zafar A, Comlekci Abdurrahman, Galvez Guillermo Gonzalez, Malik Rached, Pathan Md Faruque, Kumar Ajay
Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India.
Director, Department of Endocrinology, BIRDEM, Dhaka, Bangladesh.
Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):542-5. doi: 10.4103/2230-8210.182980.
Insulin degludec/insulin aspart (IDegAsp) is a modern coformulation of ultra-long-acting basal insulin degludec, with rapid-acting insulin aspart. IDegAsp provides effective, safe, well-tolerated glycemic control, with a low risk of hypoglycemia while allowing flexibility in meal patterns and timing of administration. This consensus statement describes a pragmatic framework to identify patients who may benefit from IDegAsp therapy. It highlights the utility of IDegAsp in type 2 diabetic patients who are insulin-naive, suboptimally controlled on basal or premixed insulin, or dissatisfied with basal-bolus regimens. It also describes potential IDegAsp usage in type 1 diabetic patients.
德谷胰岛素/门冬胰岛素（IDegAsp）是超长效基础胰岛素德谷胰岛素与速效门冬胰岛素的现代复方制剂。IDegAsp能提供有效、安全且耐受性良好的血糖控制，低血糖风险低，同时在进餐模式和给药时间方面具有灵活性。本共识声明描述了一个实用框架，以识别可能从IDegAsp治疗中获益的患者。它强调了IDegAsp在初治、基础胰岛素或预混胰岛素治疗血糖控制不佳或对基础-餐时胰岛素方案不满意的2型糖尿病患者中的应用价值。它还描述了IDegAsp在1型糖尿病患者中的潜在用法。
